{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:08:04Z","timestamp":1792109284048,"version":"4.4.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000276","name":"Department of Health, UK","doi-asserted-by":"crossref","award":["015\/0306"],"award-info":[{"award-number":["015\/0306"]}],"id":[{"id":"10.13039\/501100000276","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12916-019-1300-2","type":"journal-article","created":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T01:13:27Z","timestamp":1554081207000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["Improving engagement with healthcare in hepatitis C: a randomised controlled trial of a peer support intervention"],"prefix":"10.1186","volume":"17","author":[{"given":"Helen R.","family":"Stagg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Surey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"MacLellan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham R.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Charlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Abubakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,1]]},"reference":[{"key":"1300_CR1","unstructured":"Public Health England. Hepatitis C in England: 2017 report. 2017. \n                    https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/599738\/hepatitis_c_in_england_2017_report.pdf\n                    \n                  . Accessed 23 Oct 2018."},{"key":"1300_CR2","unstructured":"NHS England. NHS England sets out plans to be first in the world to eliminate Hepatitis C. 2018. \n                    https:\/\/www.england.nhs.uk\/2018\/01\/hepatitis-c-2\/\n                    \n                  . Accessed 23 Oct 2018."},{"issue":"6","key":"1300_CR3","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.drugpo.2007.09.001","volume":"19","author":"J Neale","year":"2008","unstructured":"Neale J. Homelessness, drug use and hepatitis C: a complex problem explored within the context of social exclusion. Int J Drug Policy. 2008;19(6):429\u201335.","journal-title":"Int J Drug Policy"},{"issue":"10","key":"1300_CR4","doi-asserted-by":"publisher","first-page":"605","DOI":"10.12968\/bjon.2011.20.10.605","volume":"20","author":"I Peate","year":"2011","unstructured":"Peate I. Prisoner health: HIV infection and other blood-borne viral infections. Br J Nurs. 2011;20(10):605\u20136 608, 610.","journal-title":"Br J Nurs"},{"key":"1300_CR5","unstructured":"Public Health England, Health Protection Scotland, Public Health Wales, Public Health Agency Northern Ireland. Shooting up: infections among people who inject drugs in the UK 2012. 2013. \n                    http:\/\/webarchive.nationalarchives.gov.uk\/20140629102627\/http:\/\/hpa.org.uk\/Publications\/InfectiousDiseases\/BloodBorneInfections\/ShootingUp\/1311ShootingupInfectionsamongIDUS\/\n                    \n                  . Accessed 23 Oct 2018."},{"key":"1300_CR6","unstructured":"World Health Organization. Guidelines for the screening care and treatment of persons with chronic hepatitis C infection. 2016. \n                    http:\/\/apps.who.int\/iris\/bitstream\/10665\/205035\/1\/9789241549615_eng.pdf?ua=1\n                    \n                  . Accessed 23 Oct 2018."},{"key":"1300_CR7","unstructured":"Foster G, Huskinson P. 25,000 hepatitis C patients receive new treatments. 2018. \n                    https:\/\/www.england.nhs.uk\/blog\/25000-hepatitis-c-patients-receive-new-treatments\/\n                    \n                  . Accessed 23 Oct 2018."},{"issue":"10","key":"1300_CR8","doi-asserted-by":"publisher","first-page":"e0141122","DOI":"10.1371\/journal.pone.0141122","volume":"10","author":"J MacLellan","year":"2015","unstructured":"MacLellan J, Surey J, Abubakar I, Stagg HR. Peer support workers in health: a qualitative metasynthesis of their experiences. PLoS One. 2015;10(10):e0141122.","journal-title":"PLoS One"},{"key":"1300_CR9","first-page":"15","volume":"1","author":"TF Kresina","year":"2008","unstructured":"Kresina TF, Sylvestre D, Seeff L, Litwin AH, Hoffman K, Lubran R, et al. Hepatitis infection in the treatment of opioid dependence and abuse. Subst Abuse. 2008;1:15\u201361.","journal-title":"Subst Abuse"},{"issue":"6","key":"1300_CR10","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1097\/COH.0b013e32834bcb36","volume":"6","author":"J Grebely","year":"2011","unstructured":"Grebely J, Tyndall MW. Management of HCV and HIV infections among people who inject drugs. Curr Opin HIV AIDS. 2011;6(6):501\u20137.","journal-title":"Curr Opin HIV AIDS"},{"key":"1300_CR11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.drugpo.2017.08.004","volume":"50","author":"C Henderson","year":"2017","unstructured":"Henderson C, Madden A, Kelsall J. \u2018Beyond the willing & the waiting\u2019 - the role of peer-based approaches in hepatitis C diagnosis & treatment. Int J Drug Policy. 2017;50:111\u20135.","journal-title":"Int J Drug Policy."},{"issue":"3","key":"1300_CR12","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s10900-007-9083-3","volume":"33","author":"SH Mehta","year":"2008","unstructured":"Mehta SH, Genberg BL, Astemborski J, Kavasery R, Kirk GD, Vlahov D, et al. Limited uptake of hepatitis C treatment among injection drug users. J Community Health. 2008;33(3):126\u201333.","journal-title":"J Community Health"},{"issue":"Suppl 2","key":"1300_CR13","doi-asserted-by":"publisher","first-page":"S129","DOI":"10.1093\/cid\/cit302","volume":"57","author":"G Robaeys","year":"2013","unstructured":"Robaeys G, Grebely J, Mauss S, Bruggmann P, Moussalli J, De Gottardi A, et al. Recommendations for the management of hepatitis C virus infection among people who inject drugs. Clin Infect Dis. 2013;57(Suppl 2):S129\u201337.","journal-title":"Clin Infect Dis"},{"key":"1300_CR14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1477-7517-5-8","volume":"5","author":"J Norman","year":"2008","unstructured":"Norman J, Walsh NM, Mugavin J, Stoove MA, Kelsall J, Austin K, et al. The acceptability and feasibility of peer worker support role in community based HCV treatment for injecting drug users. Harm Reduct J. 2008;5:8.","journal-title":"Harm Reduct J"},{"issue":"1","key":"1300_CR15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1080\/13557858.2015.1004870","volume":"21","author":"C Treloar","year":"2016","unstructured":"Treloar C, Jackson C, Gray R, Newland J, Wilson H, Saunders V, et al. Care and treatment of hepatitis C among aboriginal people in New South Wales, Australia: implications for the implementation of new treatments. Ethn Health. 2016;21(1):39\u201357.","journal-title":"Ethn Health"},{"issue":"1","key":"1300_CR16","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s40271-013-0005-4","volume":"6","author":"MM Manos","year":"2013","unstructured":"Manos MM, Ho CK, Murphy RC, Shvachko VA. Physical, social, and psychological consequences of treatment for hepatitis C: a community-based evaluation of patient-reported outcomes. Patient. 2013;6(1):23\u201334.","journal-title":"Patient."},{"issue":"5","key":"1300_CR17","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.drugpo.2007.01.010","volume":"18","author":"DL Sylvestre","year":"2007","unstructured":"Sylvestre DL, Zweben JE. Integrating HCV services for drug users: a model to improve engagement and outcomes. Int J Drug Policy. 2007;18(5):406\u201310.","journal-title":"Int J Drug Policy."},{"issue":"1","key":"1300_CR18","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12954-017-0192-8","volume":"14","author":"AW Batchelder","year":"2017","unstructured":"Batchelder AW, Cockerham-Colas L, Peyser D, Reynoso SP, Soloway I, Litwin AH. Perceived benefits of the hepatitis C peer educators: a qualitative investigation. Harm Reduct J. 2017;14(1):67.","journal-title":"Harm Reduct J"},{"issue":"3","key":"1300_CR19","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1097\/MEG.0b013e32832a8c4c","volume":"22","author":"J Grebely","year":"2010","unstructured":"Grebely J, Knight E, Genoway KA, Viljoen M, Khara M, Elliott D, et al. Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support. Eur J Gastroenterol Hepatol. 2010;22(3):270\u20137.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"1300_CR20","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.drugpo.2017.05.031","volume":"47","author":"O Bonnington","year":"2017","unstructured":"Bonnington O, Harris M. Tensions in relation: how peer support is experienced and received in a hepatitis C treatment intervention. Int J Drug Policy. 2017;47:221\u20139.","journal-title":"Int J Drug Policy."},{"issue":"10","key":"1300_CR21","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.drugpo.2015.01.005","volume":"26","author":"C Treloar","year":"2015","unstructured":"Treloar C, Rance J, Bath N, Everingham H, Micallef M, Day C, et al. Evaluation of two community-controlled peer support services for assessment and treatment of hepatitis C virus infection in opioid substitution treatment clinics: the ETHOS study, Australia. Int J Drug Policy. 2015;26(10):992\u20138.","journal-title":"Int J Drug Policy."},{"issue":"2","key":"1300_CR22","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1353\/hpu.2014.0096","volume":"25","author":"RJ Roose","year":"2014","unstructured":"Roose RJ, Cockerham-Colas L, Soloway I, Batchelder A, Litwin AH. Reducing barriers to hepatitis C treatment among drug users: an integrated hepatitis C peer education and support program. J Health Care Poor Underserved. 2014;25(2):652\u201362.","journal-title":"J Health Care Poor Underserved"},{"issue":"10","key":"1300_CR23","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.drugpo.2015.07.006","volume":"26","author":"J Keats","year":"2015","unstructured":"Keats J, Micallef M, Grebely J, Hazelwood S, Everingham H, Shrestha N, et al. Assessment and delivery of treatment for hepatitis C virus infection in an opioid substitution treatment clinic with integrated peer-based support in Newcastle, Australia. Int J Drug Policy. 2015;26(10):999\u20131006.","journal-title":"Int J Drug Policy."},{"key":"1300_CR24","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.drugpo.2017.11.014","volume":"52","author":"T Kikvidze","year":"2018","unstructured":"Kikvidze T, Luhmann N, Avril E, Butsashvili M, Labartkava K, Etienne A, et al. Harm reduction-based and peer-supported hepatitis C treatment for people who inject drugs in Georgia. Int J Drug Policy. 2018;52:16\u20139.","journal-title":"Int J Drug Policy."},{"issue":"5","key":"1300_CR25","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.drugpo.2007.01.009","volume":"18","author":"J Grebely","year":"2007","unstructured":"Grebely J, Genoway K, Khara M, Duncan F, Viljoen M, Elliott D, et al. Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection. Int J Drug Policy. 2007;18(5):437\u201343.","journal-title":"Int J Drug Policy."},{"issue":"11","key":"1300_CR26","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.drugpo.2015.05.004","volume":"26","author":"N Ford","year":"2015","unstructured":"Ford N, Wiktor S, Kaplan K, Andrieux-Meyer I, Hill A, Radhakrishnan P, et al. Ten priorities for expanding access to HCV treatment for people who inject drugs in low- and middle-income countries. Int J Drug Policy. 2015;26(11):1088\u201393.","journal-title":"Int J Drug Policy."},{"key":"1300_CR27","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jsat.2016.04.001","volume":"67","author":"A Arain","year":"2016","unstructured":"Arain A, De Sousa J, Corten K, Verrando R, Thijs H, Mathei C, et al. Pilot study: combining formal and peer education with FibroScan to increase HCV screening and treatment in persons who use drugs. J Subst Abus Treat. 2016;67:44\u20139.","journal-title":"J Subst Abus Treat"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-019-1300-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12916-019-1300-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-019-1300-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,30]],"date-time":"2020-03-30T23:10:31Z","timestamp":1585609831000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-019-1300-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1300"],"URL":"https:\/\/doi.org\/10.1186\/s12916-019-1300-2","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,1]]},"assertion":[{"value":"23 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was reviewed and approved by the National Research Ethics Service Committee London, Brent (13\/LO\/0077), UK. All participants gave written informed consent to be part of the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HRS reports funding from the Department of Health during the course of the study. JS, JM and MF report funding from the Department of Health and the National Institute for Health Research Clinical Research Network, UK, during the conduct of the study. GF reports personal fees from AbbVie, Gilead and Merck during the conduct of the study. The other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"71"}}